Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QAMR | ISIN: US0198181036 | Ticker-Symbol:
NASDAQ
27.03.24
20:44 Uhr
0,758 US-Dollar
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ALLOVIR INC Chart 1 Jahr
5-Tage-Chart
ALLOVIR INC 5-Tage-Chart

Aktuelle News zur ALLOVIR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
15.03.Allovir, Inc. - 10-K, Annual Report1
14.03.Holzer & Holzer, LLC: Holzer & Holzer, LLC Reminds Shareholders of the March 19, 2024 Lead Plaintiff Deadline in the AlloVir, Inc. (ALVR) Class Action - Nationally Ranked Investors Rights Firm Encourages Investors With Significant Losses to Contact th1
12.02.Allovir, Inc. - 8-K, Current Report1
05.01.AlloVir Layoffs 2024: What to Know About the Latest ALVR Job Cuts4
05.01.Reeling from triple phase 3 failure, AlloVir cuts 95% of workforce2
04.01.Allovir, Inc. - 8-K, Current Report1
22.12.23Why Is Penny Stock Cell Therapy Focused AlloVir Stock Plummeting Today?5
22.12.23AlloVir's shares plunge 64% as cell therapy biotech weighs options in wake of triple phase 3 disaster11
22.12.23AlloVir scraps late-stage studies testing lead cell therapy4
22.12.23AlloVir falls on scrapping antiviral cell therapy trials, plans to explore options3
22.12.23Allovir, Inc. - 8-K, Current Report2
22.12.23AlloVir Inc.: AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy499Company to discontinue its three Phase 3 posoleucel studies following separate, pre-planned DSMB futility analyses concluding the studies were unlikely to meet their primary endpoints; no safety concerns...
► Artikel lesen
02.11.23Allovir, Inc. - 10-Q, Quarterly Report1
02.11.23AlloVir GAAP EPS of -$0.39 beats by $0.013
02.11.23Allovir, Inc. - 8-K, Current Report1
02.11.23AlloVir Reports Third Quarter 2023 Financial Results191WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today reported financial results from the third quarter ended September...
► Artikel lesen
03.08.23AlloVir Reports Second Quarter 2023 Financial Results271WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today reported financial results from the second quarter ended June...
► Artikel lesen
22.06.23Pre-market Movers: ShiftPixy, Root, Inc., Avid Bioservices, AlloVir, KWESST Micro Systems863SAINT PAUL (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.25 A.M. ET).In the GreenShiftPixy, Inc. (PIXY) is up over 92% at $2.54. Root...
► Artikel lesen
04.05.23AlloVir Reports First Quarter 2023 Financial Results292WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today reported financial results from the first quarter ended March 31, 2023....
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1